ERC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 14 (2) 189-206    DOI: 10.1677/ERC-06-0068
Copyright © 2007 by the Society for Endocrinology.
This Article
Right arrow Free Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vona-Davis, L.
Right arrow Articles by Rose, D. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vona-Davis, L.
Right arrow Articles by Rose, D. P

REVIEW

Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression

Linda Vona-Davis and David P Rose

Department of Surgery & Mary Babb Randolph Cancer Center, West Virginia University, PO Box 9238, Morgantown, West Virginia 26506, USA

(Requests for offprints should be addressed to L Vona-Davis; Email: lvdavis{at}hsc.wvu.edu)

Adipokines (leptin, adiponectin, and hepatocyte growth factor (HGF)) secreted from adipose tissue have come to be recognized for their contribution to the mechanisms by which obesity and related metabolic disorders influence breast cancer risk. In this review, we discuss the direct and indirect effects of these protein factors on the biological and clinical aspects of breast cancer biology, and emphasize their distinctive modes of action through endocrine-, paracrine-, and autocrine-mediated pathways. The stimulatory effects of leptin on breast cancer growth were considered to occur primarily via activation of the estrogen receptor; however, new evidence suggests that leptin may be acting on downstream cell signaling pathways in both estrogen-dependent and -independent cell types. Another secretory adipokine, HGF, may act largely not only to promote tumor cell invasion, but also to enhance tumor growth indirectly by stimulating angiogenesis. In contrast, adiponectin, an endogenous insulin sensitizer, exerts a direct growth-inhibitory effect on tumor cells by downregulating cell proliferation and upregulating apoptosis, and also inhibits tumor-related angiogenesis.




This article has been cited by other articles:


Home page
Br. J. Sports. Med.Home page
C M Friedenreich and A E Cust
Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects
Br. J. Sports Med., August 1, 2008; 42(8): 636 - 647.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
V. Bartella, S. Cascio, E. Fiorio, A. Auriemma, A. Russo, and E. Surmacz
Insulin-Dependent Leptin Expression in Breast Cancer Cells
Cancer Res., June 15, 2008; 68(12): 4919 - 4927.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Endocrinology.